Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

MLA

Sung Yong Oh, et al. “Phase II Study of R–CVP Followed by Rituximab Maintenance Therapy for Patients with Advanced Marginal Zone Lymphoma: Consortium for Improving Survival of Lymphoma (CISL) Study.” Cancer Communications, vol. 39, no. 1, Oct. 2019, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s40880-019-0403-7.

APA

Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Dok Hyun Yoon, Deok-Hwan Yang, Won Sik Lee, Hyo Jung Kim, Ho-Young Yhim, Seong Hyun Jeong, Jong Ho Won, Suee Lee, Jee Hyun Kong, Sung-Nam Lim, Jun Ho Ji, Kyung A. Kwon, Gyeong-Won Lee, Jae Hoon Lee, Ho Sup Lee, … Cheolwon Suh. (2019). Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Communications, 39(1), 1–10. https://doi.org/10.1186/s40880-019-0403-7

Chicago

Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Dok Hyun Yoon, Deok-Hwan Yang, Won Sik Lee, et al. 2019. “Phase II Study of R–CVP Followed by Rituximab Maintenance Therapy for Patients with Advanced Marginal Zone Lymphoma: Consortium for Improving Survival of Lymphoma (CISL) Study.” Cancer Communications 39 (1): 1–10. doi:10.1186/s40880-019-0403-7.